HLA-DR_NN
-_:
,_,
CD33_NN
+_NN
,_,
CD56_NN
+_NN
,_,
CD16_NN
-_CC
myeloid\/natural_JJ
killer_NN
cell_NN
acute_JJ
leukemia_NN
:_:
a_DT
previously_RB
unrecognized_JJ
form_NN
of_IN
acute_JJ
leukemia_NN
potentially_RB
misdiagnosed_JJ
as_IN
French-American-British_JJ
acute_JJ
myeloid_JJ
leukemia-M3_NN
-LCB-_-LRB-
see_VB
comments_NNS
-RCB-_-RRB-

We_PRP
have_VBP
identified_VBN
and_CC
characterized_VBN
a_DT
previously_RB
unrecognized_JJ
form_NN
of_IN
acute_JJ
leukemia_NN
that_WDT
shares_VBZ
features_NNS
of_IN
both_CC
myeloid_JJ
and_CC
natural_JJ
killer_NN
-LRB-_-LRB-
NK_NN
-RRB-_-RRB-
cells_NNS
._.

From_IN
a_DT
consecutive_JJ
series_NN
of_IN
350_CD
cases_NNS
of_IN
adult_JJ
de_FW
novo_FW
acute_JJ
myeloid_JJ
leukemia_NN
-LRB-_-LRB-
AML_NN
-RRB-_-RRB-
,_,
we_PRP
identified_VBD
20_CD
cases_NNS
-LRB-_-LRB-
6_CD
%_NN
-RRB-_-RRB-
with_IN
a_DT
unique_JJ
immunophenotype_NN
:_:
CD33_NN
+_NN
,_,
CD56_NN
+_NN
,_,
CD11a_NN
+_NN
,_,
CD13lo_JJ
,_,
CD15lo_JJ
,_,
CD34_NN
+_CC
\/_NN
-_:
,_,
HLA-DR_NN
-_:
,_,
CD16_NN
-_:
._.

Multicolor_JJ
flow_NN
cytometric_JJ
assays_NNS
confirmed_VBD
the_DT
coexpression_NN
of_IN
myeloid_JJ
-LRB-_-LRB-
CD33_NN
,_,
CD13_NN
,_,
CD15_NN
-RRB-_-RRB-
and_CC
NK_NN
cell-associated_JJ
-LRB-_-LRB-
CD56_NN
-RRB-_-RRB-
antigens_NNS
in_IN
each_DT
case_NN
,_,
whereas_IN
reverse_JJ
transcription_NN
polymerase_NN
chain_NN
reaction_NN
-LRB-_-LRB-
RT-PCR_NN
-RRB-_-RRB-
assays_NNS
confirmed_VBD
the_DT
identity_NN
of_IN
CD56_NN
-LRB-_-LRB-
neural_JJ
cell_NN
adhesion_NN
molecule_NN
-RRB-_-RRB-
in_IN
leukemic_JJ
blasts_NNS
._.

Although_IN
two_CD
cases_NNS
expressed_VBD
CD4_NN
,_,
no_DT
case_NN
expressed_VBD
CD2_NN
,_,
CD3_NN
,_,
or_CC
CD8_NN
and_CC
no_DT
case_NN
showed_VBD
clonal_JJ
rearrangement_NN
of_IN
genes_NNS
encoding_VBG
the_DT
T-cell_NN
receptor_NN
-LRB-_-LRB-
TCR_NN
beta_NN
,_,
gamma_NN
,_,
delta_NN
-RRB-_-RRB-
._.

Leukemic_JJ
blasts_NNS
in_IN
the_DT
majority_NN
of_IN
cases_NNS
shared_VBD
unique_JJ
morphologic_JJ
features_NNS
-LRB-_-LRB-
deeply_RB
invaginated_JJ
nuclear_JJ
membranes_NNS
,_,
scant_JJ
cytoplasm_NN
with_IN
fine_JJ
azurophilic_JJ
granularity_NN
,_,
and_CC
finely_RB
granular_JJ
Sudan_NN
black_JJ
B_NN
and_CC
myeloperoxidase_NN
cytochemical_JJ
reactivity_NN
-RRB-_-RRB-
that_WDT
were_VBD
remarkably_RB
similar_JJ
to_TO
those_DT
of_IN
acute_JJ
promyelocytic_JJ
leukemia_NN
-LRB-_-LRB-
APL_NN
-RRB-_-RRB-
;_:
particularly_RB
the_DT
microgranular_JJ
variant_NN
-LRB-_-LRB-
FAB_NN
AML-M3v_NN
-RRB-_-RRB-
._.

However_RB
,_,
all_DT
20_CD
cases_NNS
lacked_VBD
the_DT
t_NN
-LRB-_-LRB-
15_CD
;_:
17_CD
-RRB-_-RRB-
and_CC
17_CD
cases_NNS
tested_VBN
lacked_VBD
the_DT
promyelocytic\/retinoic_JJ
acid_NN
receptor_NN
alpha_NN
-LRB-_-LRB-
RAR_NN
alpha_NN
-RRB-_-RRB-
fusion_NN
transcript_NN
in_IN
RT-PCR_NN
assays_NNS
;_:
12_CD
cases_NNS
had_VBD
46_CD
,_,
XX_NN
or_CC
46_CD
,_,
XY_NN
karyotypes_NNS
,_,
whereas_IN
2_CD
cases_NNS
had_VBD
abnormalities_NNS
of_IN
chromosome_NN
17q_NN
:_:
1_CD
with_IN
del_NN
17_CD
-LRB-_-LRB-
q25_NN
-RRB-_-RRB-
and_CC
the_DT
other_JJ
with_IN
t_NN
-LRB-_-LRB-
11_CD
;_:
17_CD
-RRB-_-RRB-
-LRB-_-LRB-
q23_NN
;_:
q21_NN
-RRB-_-RRB-
and_CC
the_DT
promyelocytic_JJ
leukemia_NN
zinc_NN
finger\/RAR_NN
alpha_NN
fusion_NN
transcript_NN
._.

All_DT
cases_NNS
tested_VBN
-LRB-_-LRB-
6\/20_CD
-RRB-_-RRB-
,_,
including_VBG
the_DT
case_NN
with_IN
t_NN
-LRB-_-LRB-
11_CD
;_:
17_CD
-RRB-_-RRB-
,_,
failed_VBD
to_TO
differentiate_VB
in_FW
vitro_FW
in_IN
response_NN
to_TO
all-trans_JJ
retinoic_JJ
acid_NN
-LRB-_-LRB-
ATRA_NN
-RRB-_-RRB-
,_,
suggesting_VBG
that_IN
these_DT
cases_NNS
may_MD
account_VB
for_IN
some_DT
APLs_NNS
that_WDT
have_VBP
not_RB
shown_VBN
a_DT
clinical_JJ
response_NN
to_TO
ATRA_NN
._.

Four_CD
of_IN
6_CD
cases_NNS
tested_VBN
showed_VBD
functional_JJ
NK_NN
cell-mediated_JJ
cytotoxicity_NN
,_,
suggesting_VBG
a_DT
relationship_NN
between_IN
these_DT
unique_JJ
CD33_NN
+_NN
,_,
CD56_NN
+_NN
,_,
CD16_NN
-_:
acute_JJ
leukemias_NNS
and_CC
normal_JJ
CD56_NN
+_JJ
,_,
CD16_NN
-_:
NK_NN
precursor_NN
cells_NNS
._.

Using_VBG
a_DT
combination_NN
of_IN
panning_NN
and_CC
multiparameter_NN
flow_NN
cytometric_JJ
sorting_NN
,_,
we_PRP
identified_VBD
a_DT
normal_JJ
CD56_NN
+_JJ
,_,
CD33_NN
+_JJ
,_,
CD16_NN
-_:
counterpart_NN
cell_NN
at_IN
a_DT
frequency_NN
of_IN
1_CD
%_NN
to_TO
2_CD
%_NN
in_IN
the_DT
peripheral_JJ
blood_NN
of_IN
healthy_JJ
individuals_NNS
._.

Our_PRP$
studies_NNS
suggest_VBP
that_IN
this_DT
form_NN
of_IN
acute_JJ
leukemia_NN
may_MD
arise_VB
from_IN
transformation_NN
of_IN
a_DT
precursor_NN
cell_NN
common_JJ
to_TO
both_CC
the_DT
myeloid_JJ
and_CC
NK_NN
cell_NN
lineages_NNS
;_:
thus_RB
we_PRP
propose_VBP
the_DT
designation_NN
myeloid\/NK_JJ
acute_JJ
leukemia_NN
._.

Recognition_NN
of_IN
this_DT
new_JJ
leukemic_JJ
entity_NN
will_MD
be_VB
important_JJ
in_IN
distinguishing_VBG
these_DT
ATRA-nonresponsive_JJ
cases_NNS
from_IN
ATRA-responsive_JJ
true_JJ
APL_NN
._.

